Germany, Accelerator, Education, 2018

Wild Card contestants pitch at end of training and mentoring session

14th August 2019

EIT Health will support the best ideas

Four EIT Health Wild Card teams pitched their ideas for healthcare innovation on 17-18 July 2018 in Munich, in the culmination of a nine-week training designed to help them validate their business models. A panel of experts will choose which of these ideas will earn EIT Health support.

The finalists have been working with business experts on validating their ideas and practising their pitching skills, through the Wild Card and CIMIT CRAASH programme. The teams also looked at skills gaps and identified with their mentors the particular needs required to continue progressing with their ideas. As a result, some teams have acquired new members with dedicated skill sets and experience that will help ensure their projects’ success.

The 17 and 18 July pitching sessions gave teams a last opportunity to work with their business mentors and give their final pitches to the judging panel – with the chance of winning this year’s Wild Card and receiving support for their ideas for the next two years.

With four exciting projects remaining in the programme, the judging panel will have a tough decision on which show the greatest potential to transform smart health and antibiotic resistance in Europe.

The panel of judges includes: John Collins (CIMIT), Derek Young (i360 Medical), Kerry Ritz (Great River Ventures), Markus Wilhelms (usMIMA & Mowoot). Panelists from within EIT Health are: CEO Jan-Philipp Beck, Director of Business Creation Kurt Höller, Director of Innovation Jorge Fernández García and Managing Director CLC Germany Katharina Ladewig.

Speaking at the event, EIT Health CEO Jan-Philipp Beck commented “We started Wild Card with really high ambitions to create something new, attract the brightest talents with great ideas and support them in addressing major healthcare challenges in Europe.”

“This first year went really well and has been a fantastic experience for us all. We are looking forward to hearing the judging panel’s final deliberations and announcing our first ever Wild Card winners soon.”

The final teams are:

  • Predicare
  • ABTrace
  • DX-Labtrack
  • i-Ophthalmology

About the Wild Card Projects

Wild Card Projects identify and support truly ground-breaking ideas and projects, focusing on applied research, entrepreneurial ideas and innovative thinking to address healthcare challenges and improve health outcomes for Europe’s citizens.

The challenges are based on proposals from all EIT Health Partners, who were solicited for their ideas. This process was conducted in 2017 to develop the challenges that are expected shape the Wild Card Projects proposals in 2018:

Smart Health: Personalised patient data can revolutionise diagnosis and treatment – but the real problem is capturing, storing and making sense of it. The Smart Health challenge sets entrepreneurs the task of building new solutions that use Artificial Intelligence to quickly interpret large, unstructured data sets within existing regulatory frame works, allowing healthcare professionals across the EU to improve patient care.

Fight Back: Left unchecked, antibiotic resistance could become Europe’s biggest health crisis. Simple hospital procedures will carry risk again, while old, dangerous diseases could become widespread. The Fight Back challenge tasks entrepreneurs with building innovative solutions to take on antibiotic resistance. The most effective solution must raise awareness of the problem, while also enabling new processes and methodologies to manage it across the EU healthcare landscape.

Find out more about the Wild Card Projects here.

EIT Health-supported Vitadio earns permanent DiGA status

EIT Health-supported Vitadio earns permanent DiGA status

Learn how we helped them grow.

Find out more

Skill Sync: Bridging Europe's AI skills gap

Skill Sync: Bridging Europe's AI skills gap

Learn how we're addressing the AI skills gap.

Find out more

EIT Health-supported start-up Ochre Bio signs $1BN+ deal with Boehringer Ingelheim

EIT Health-supported start-up Ochre Bio signs $1BN+ deal with Boehringer Ingelheim

Learn how we supported their journey.

Find out more